AIM ImmunoTech Inc

AIM ImmunoTech Inc. (AIM) is a U.S.-based biotechnology company with a robust pipeline of therapeutics for cancer and immune-deficiency disorders, positioning it for growth in a resilient market landscape.

AIM ImmunoTech Inc. has announced positive mid-year data from its Phase 2 study, evaluating a combination therapy for pancreatic cancer, which could potentially accelerate the development timeline for the treatment.

AIM ImmunoTech Inc. is a biotech company dedicated to developing innovative therapeutics for cancer and immune disorders, with a focus on harnessing the immune system to combat diseases.